CHRS stock forecast, quote, news & analysis
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers... Show more
Why Coherus BioSciences (CHRS) Stock Is Down -51% in the Last 30 Days
Key Takeaways
- Coherus BioSciences shares fell roughly 51% over the last 30 days, sliding from about $1.05 to near $0.52.
- The decline accelerated after third-quarter 2026 results that missed revenue estimates and included a cut to full-year LOQTORZI guidance.
- Management announced an approximately 30% workforce reduction and disclosed a going-concern warning with less than 12 months of cash runway.
- LOQTORZI revenue reached $14.0 million in the third quarter, up 25% year over year, but sequential growth of just 3% missed the company's own 10%–15% target.
- A promising esophageal cancer signal for tagmokitug was overshadowed by balance-sheet and financing concerns.
- Over the last quarter, the stock has fallen roughly 55%, from about $1.15 in mid-August.
- For additional detail on the company's Price Targets, Earnings, and Forecast, explore the dedicated pages.
- Explore Trending AI Robots to see how automated trading strategies are positioning across the market.
Coherus BioSciences (CHRS) Company Overview and Market Position
Coherus BioSciences, Inc., which now operates as Coherus Oncology, is a commercial-stage biopharmaceutical company focused on oncology. Its lead product is LOQTORZI (toripalimab-tpzi), an anti-PD-1 antibody approved by the U.S. Food and Drug Administration for the treatment of recurrent, locally advanced, or metastatic nasopharyngeal carcinoma (NPC). The company has been transforming itself from a biosimilars business — it previously marketed UDENYCA, a biosimilar to pegfilgrastim — into an innovative oncology company, having divested its biosimilars franchise to sharpen focus on its cancer pipeline. Its primary clinical asset is tagmokitug, an investigational antibody designed to deplete regulatory T cells (Tregs), which is being developed in combination with toripalimab, with development now concentrated on esophageal cancer. Investors follow CHRS closely because its outlook hinges on LOQTORZI's commercial ramp and the financing needed to advance its clinical programs.
Coherus BioSciences (CHRS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CHRS shares have fallen approximately 51%, declining from a close near $1.05 in mid-October to roughly $0.52 by mid-November. The selling was concentrated in the days following the company's third-quarter earnings release, with the stock dropping sharply as financing and going-concern concerns came into focus.
The quarterly trend is even more pronounced. From a level of about $1.15 in mid-August, the shares have lost roughly 55% through mid-November, reflecting a sustained, multi-month decline rather than an isolated single-day event. The stock has drifted lower across the quarter as investor confidence in the company's path to financial self-sufficiency weakened.
What Drove CHRS Stock Price in the Last 30 Days
The 30-day decline was driven primarily by the company's third-quarter 2026 results and its accompanying strategic announcement. Coherus reported net revenue of $14.27 million, below the consensus estimate near $15.9 million, with LOQTORZI net sales of $14.0 million. Sequential LOQTORZI growth of 3% fell well short of the 10%–15% pace management had previously guided.
More consequential than the miss was management's reset of expectations. The company cut full-year 2026 LOQTORZI guidance to $54 million–$57 million from $57 million–$62 million, announced an approximately 30% headcount reduction (from roughly 140 to 100 employees), and narrowed its pipeline focus to esophageal cancer. Critically, the company disclosed a going-concern warning in its quarterly filing, stating that its cash runway is less than 12 months absent cost reductions, milestone payments, or partnership proceeds. Cash and investments fell to $83.6 million at the end of the quarter, down from $105.3 million three months earlier. These disclosures elevated concerns about dilution and financing risk, overshadowing a positive esophageal cancer data readout for tagmokitug and triggering the sharp sell-off.
What Drove CHRS Stock Performance Over the Last Quarter
The quarterly decline reflects a broader narrative of a company still spending well above the revenue its marketed product generates. Coherus has been working to transition from a biosimilars player to a focused oncology company, but LOQTORZI's commercial uptake has been slower than needed to offset operating costs. With quarterly product sales around $14 million and core operating losses in the tens of millions of dollars, the company's cash position has eroded steadily through the year.
Across the quarter, investors repriced the shares as management's earlier assurances about funding through clinical readouts gave way to a going-concern disclosure. The refinancing of a term loan added only about $11.5 million in net cash, and a UDENYCA earn-out milestone was narrowly missed, leaving the company increasingly reliant on cost cuts, ex-U.S. partnering, and potential milestone payments to extend its runway. The result has been a steady, downward drift in the share price punctuated by sharp declines around earnings.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this section, which is updated to reflect changing market conditions. These bots vary widely in strategy, holding timeframe, and performance metrics, giving traders a view into how algorithmic approaches are adapting across different stocks and sectors. For those interested in how AI-driven systems are positioning themselves in volatile names, the page offers a useful, data-focused reference point. Explore the page to review the currently featured strategies and their track records.
CHRS Stock Forecast Drivers: What Investors Should Watch Next
Several factors will shape CHRS shares going forward. First, investors will monitor the U.S. FDA action date for the drug-product portion of the toripalimab manufacturing transfer application, which management indicated falls on November 30. Second, the company plans to engage the FDA on a development path for tagmokitug in second-line esophageal cancer, with any expedited-approval pathway a potential catalyst. Third, ex-U.S. partnering discussions for tagmokitug could bring upfront payments that ease the cash crunch, while the disputed UDENYCA earn-out milestone remains unresolved. Finally, LOQTORZI's fourth-quarter trajectory — management guided to roughly a $15 million quarter — and the company's ability to secure additional financing without excessive dilution will be central to investor sentiment. These are factual developments to monitor rather than signals of any specific outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CHRS in -9.79% downward trend, sliding for three consecutive days on November 13, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CHRS declined for three days, in 296 of 326 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In 75 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 43 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
The Aroon Indicator for CHRS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 182 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (3.498). P/E Ratio (-0.733) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of biologic therapeutics for oncology and inflammatory diseases
Industry Biotechnology